At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise
What happens when you put hemp farmers, moms against pot, and Ph.D. scientists in a room to discuss #CBD?
by Nicholas Florko
May 31, 2019
3 minutes
SILVER SPRING, Md. — By 10:30 a.m., a panel of the Food and Drug Administration’s top regulators had already heard from more than 50 different people, all eager to squeeze their hopes or concerns about CBD, the booming marijuana-adjacent compound companies are suddenly adding to everything from dog food to dietary supplements, into the short speaking time they were granted.
There were mothers claiming marijuana drove their children to suicide, millennial entrepreneurs who struggled for a good answer
You’re reading a preview, subscribe to read more.
Start your free 30 days